Biocon is expecting to invest $200 million (around Rs 1,500 crore) on capital expenditure (capex) in the current fiscal year (FY21), split equally between small molecules and the biosimilars businesses. The capex will be funded through a combination of contribution from internal accruals, debt raise as well as additional private equity investment in Biocon Biologics.
The company's capital expenditure stood at Rs 974.2 crore during 2019-20. Last fiscal, the company invested in a new manufacturing facility in Visakhapatnam for immunosuppressant products, which comes under the small molecules segment.
Biocon is India’s largest and Asia’s leading Biotechnology Company with a strategic focus on biopharmaceuticals and research services. It is a fully integrated, innovation driven biopharma enterprise offering affordable solutions for chronic diseases to patient's worldwide.
